GUARD Stock Overview
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Guard Therapeutics International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr29.80 |
| 52 Week High | kr49.80 |
| 52 Week Low | kr5.10 |
| Beta | -0.020 |
| 1 Month Change | 65.56% |
| 3 Month Change | 24.17% |
| 1 Year Change | 374.90% |
| 3 Year Change | -62.04% |
| 5 Year Change | -52.70% |
| Change since IPO | -99.68% |
Recent News & Updates
Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky
Apr 18
Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely
Jan 04Recent updates
Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky
Apr 18Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely
Jan 04Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely
Sep 20Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans
Apr 06We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate
Sep 09Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation
Feb 19We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate
Aug 17Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth
Apr 19Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation
Jan 04Shareholder Returns
| GUARD | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | -0.7% |
| 1Y | 374.9% | -3.4% | 4.4% |
Return vs Industry: GUARD exceeded the Swedish Biotechs industry which returned -5.3% over the past year.
Return vs Market: GUARD exceeded the Swedish Market which returned 10.3% over the past year.
Price Volatility
| GUARD volatility | |
|---|---|
| GUARD Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: GUARD's share price has been volatile over the past 3 months.
Volatility Over Time: GUARD's weekly volatility has decreased from 35% to 12% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 12 | Tobias Agervald | guardtherapeutics.com |
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019.
Guard Therapeutics International AB (publ) Fundamentals Summary
| GUARD fundamental statistics | |
|---|---|
| Market cap | kr299.84m |
| Earnings (TTM) | -kr113.32m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs GUARD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUARD income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr113.32m |
| Earnings | -kr113.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GUARD perform over the long term?
See historical performance and comparison